Senestech, Inc. (NASDAQ:SNES) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Friday.

According to Zacks, “SenesTech, Inc. developed technology for managing animal pest populations through fertility control as opposed to a lethal approach. The Company’s fertility control product candidate, ContraPest(R), will be marketed for use initially in controlling rat infestations. SenesTech, Inc. is based in Flagstaff, Arizona. “

Shares of Senestech (SNES) opened at 1.83 on Friday. Senestech has a 12-month low of $1.83 and a 12-month high of $10.69. The firm’s market capitalization is $18.89 million. The firm has a 50-day moving average of $2.05 and a 200 day moving average of $4.83.

Senestech (NASDAQ:SNES) last issued its earnings results on Thursday, August 10th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.07). The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.10 million. On average, equities research analysts expect that Senestech will post ($1.30) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first published by Daily Political and is owned by of Daily Political. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/09/17/senestech-inc-snes-stock-rating-lowered-by-zacks-investment-research.html.

In related news, COO Andrew Altman bought 20,000 shares of the business’s stock in a transaction that occurred on Friday, August 18th. The shares were acquired at an average cost of $2.77 per share, with a total value of $55,400.00. Following the completion of the purchase, the chief operating officer now directly owns 2,600 shares in the company, valued at $7,202. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Grover T. Wickersham bought 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The shares were bought at an average cost of $2.85 per share, for a total transaction of $42,750.00. Following the completion of the purchase, the director now owns 238,600 shares of the company’s stock, valued at $680,010. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 54,100 shares of company stock worth $155,730 and have sold 13,411 shares worth $35,333. 27.40% of the stock is owned by corporate insiders.

A hedge fund recently bought a new stake in Senestech stock. White Pine Capital LLC bought a new position in shares of Senestech, Inc. (NASDAQ:SNES) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 19,250 shares of the company’s stock, valued at approximately $110,000. White Pine Capital LLC owned approximately 0.19% of Senestech as of its most recent SEC filing. 15.34% of the stock is currently owned by institutional investors.

About Senestech

SenesTech, Inc is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes.

Receive News & Ratings for Senestech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senestech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.